Inactive Instrument
A.P. Pharma, Inc. Stock Other OTC
Stocks
US00202J2033
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-26 | Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification | MT |
| 06-03 | Needham Downgrades Heron Therapeutics to Hold From Buy | MT |
| Market Cap | 96.82M 83.85M 78.17M 71.89M 136M 9.21B 137M 919M 361M 4.61B 364M 356M 15.26B | P/E 2026 * |
-7.87x | P/E 2027 * | -51.2x |
|---|---|---|---|---|---|
| Enterprise Value | 96.82M 83.85M 78.17M 71.89M 136M 9.21B 137M 919M 361M 4.61B 364M 356M 15.26B | EV / Sales 2026 * |
0.58x | EV / Sales 2027 * | 0.55x |
| Free-Float |
99.03% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: A.P. Pharma, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Collard
CEO | Chief Executive Officer | 60 | 2023-04-02 |
Ira Duarte
DFI | Director of Finance/CFO | 57 | 2023-06-15 |
Mark Hensley
COO | Chief Operating Officer | 43 | 2025-04-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Craig Johnson
BRD | Director/Board Member | 64 | 2014-01-12 |
Christian Waage
BRD | Director/Board Member | 59 | 2016-06-21 |
| Director/Board Member | 51 | 2021-09-19 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.35% | +19.90% | +60.59% | +95.21% | 62.53B | |
| +2.83% | -3.03% | +27.40% | +67.25% | 52.43B | |
| +0.91% | -0.83% | -17.01% | -6.42% | 23.1B | |
| +0.27% | -3.98% | -11.28% | +352.77% | 21.4B | |
| +0.40% | +5.29% | +30.11% | -9.63% | 21.17B | |
| +0.75% | -0.84% | +33.80% | -25.25% | 17.76B | |
| +9.88% | +19.73% | +229.67% | +385.49% | 15.47B | |
| +2.08% | -3.28% | +21.67% | +564.59% | 14.68B | |
| +1.25% | +2.48% | +51.36% | +180.00% | 14.08B | |
| Average | +2.52% | +3.65% | +47.37% | +178.22% | 26.96B | |
| Weighted average by Cap. | +2.76% | +4.59% | +42.95% | +136.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 166M 143M 134M 123M 232M 15.75B 235M 1.57B 617M 7.88B 622M 608M 26.1B | 176M 152M 142M 131M 247M 16.73B 249M 1.67B 655M 8.37B 661M 646M 27.72B |
| Net income | -12.35M -10.7M -9.97M -9.17M -17.31M -1.17B -17.51M -117M -45.99M -588M -46.38M -45.36M -1.95B | -2M -1.73M -1.61M -1.49M -2.8M -190M -2.84M -18.97M -7.45M -95.15M -7.51M -7.35M -315M |
| Net Debt | - | - |
Employees
-
Calendar
Select your edition
All financial news and data tailored to specific country editions
